Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 56

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 56
---
                                                                                          
 Use                                                                                              |     | Further                                            
 Funding Required                                   |
| Nano-Mupirocin  |     | $2,420,000 (approx. 55%) |     | Finalize GMP manufacturing                                                                       
 process (CMC), bioanalytical methods, IND-enabling toxicology studies, and initiate IND prep.    |     | Yes – ~$3.5M additional funding needed for         
 Phase 1.                                           |
| Nano-ARB        |     | $1,100,000 (approx. 25%) |     | Conduct large-animal                                                                             
 PK/PD and BP safety studies, initial tumor model studies, and scale-up manufacturing assessment. |     | Yes – ~$2M needed to complete IND-enabling         
 studies.                                           |
| General & Admin |     | $880,000 (approx. 20%)   |     | Salaries, legal, IP, audit,                                                                      
 and other operating costs.                                                                       |     | Covered by proceeds; no additional funds required. |

If we raise less than the full offering amount,
we intend to prioritize activities related to our lead program (Nano-Mupirocin), and delay or reduce certain planned expenditures, including
clinical trial initiation, until additional financing becomes available.

To fully execute the Phase 1 and 2 clinical
trial for Nano-Mupirocin and to advance the Nano-ARB program through IND-enabling studies, we may require additional funds beyond the
net proceeds of this offering. We intend to pursue such funding through additional financings, strategic partnerships, or non-dilutive
sources such as grants.

The use of the proceeds represents management’s
estimates based on current business and economic conditions. We will retain broad discretion over the use of the net proceeds of this
offering which may result in an allocation of net proceeds in differing amounts than those listed above, or in entirely new areas. The
amount and timing of these proposed expenditures will depend on a number of factors, including the progress product development programs,
and any unforeseen cash needs. As a result, you will be relying on the judgment of our management with regard to the use of these net
proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that the proceeds will be used in a way that does not yield a favorable, or any, return for us. Pending application of
the net proceeds as described above, we intend to invest